Center for Reproductive Medicine, Jiangxi Maternal and Child Health Hospital, 318 Bayi Avenue, Nanchang, 330006, China.
School of Basic Medicine, Nanchang University, Nanchang, China.
Biol Res. 2022 Aug 12;55(1):26. doi: 10.1186/s40659-022-00395-1.
Unsubstantiated concerns have been raised on the potential correlation between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infertility, leading to vaccine hesitancy in reproductive-aged population. Herein, we aim to evaluate the impact of inactivated SARS-CoV-2 vaccination on embryo ploidy, which is a critical indicator for embryo quality and pregnancy chance.
This was a retrospective cohort study of 133 patients who underwent preimplantation genetic testing for aneuploidy (PGT-A) cycles with next-generation sequencing technology from June 1st 2021 to March 17th 2022 at a tertiary-care medical center in China. Women fully vaccinated with two doses of Sinopharm or Sinovac inactivated vaccines (n = 66) were compared with unvaccinated women (n = 67). The primary outcome was the euploidy rate per cycle. Multivariate linear and logistic regression analyses were performed to adjust for potential confounders.
The euploidy rate was similar between vaccinated and unvaccinated groups (23.2 ± 24.6% vs. 22.6 ± 25.9%, P = 0.768), with an adjusted β of 0.01 (95% confidence interval [CI]: -0.08-0.10). After frozen-thawed single euploid blastocyst transfer, the two groups were also comparable in clinical pregnancy rate (75.0% vs. 60.0%, P = 0.289), with an adjusted odds ratio of 6.21 (95% CI: 0.76-50.88). No significant associations were observed between vaccination and cycle characteristics or other laboratory and pregnancy outcomes.
Inactivated SARS-CoV-2 vaccination had no detrimental impact on embryo ploidy during in vitro fertilization treatment. Our finding provides further reassurance for vaccinated women who are planning to conceive. Future prospective cohort studies with larger datasets and longer follow-up are needed to confirm the conclusion.
人们对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫苗接种与不孕之间可能存在关联的担忧尚未得到证实,这导致了生殖年龄段人群对疫苗的犹豫。在此,我们旨在评估灭活的 SARS-CoV-2 疫苗接种对胚胎倍性的影响,胚胎倍性是胚胎质量和妊娠机会的关键指标。
这是一项回顾性队列研究,纳入了 2021 年 6 月 1 日至 2022 年 3 月 17 日在中国一家三级医疗中心接受下一代测序技术的胚胎植入前遗传学检测-非整倍体(PGT-A)周期的 133 名患者。将完全接种两剂国药或科兴灭活疫苗的女性(n=66)与未接种疫苗的女性(n=67)进行比较。主要结局是每个周期的整倍体率。采用多元线性和逻辑回归分析来调整潜在混杂因素。
接种组和未接种组的整倍体率相似(23.2±24.6%比 22.6±25.9%,P=0.768),调整后的β值为 0.01(95%置信区间:-0.08-0.10)。在冻融后单枚整倍体囊胚移植后,两组的临床妊娠率也相似(75.0%比 60.0%,P=0.289),调整后的优势比为 6.21(95%置信区间:0.76-50.88)。未发现疫苗接种与周期特征或其他实验室和妊娠结局之间存在显著关联。
在体外受精治疗中,灭活的 SARS-CoV-2 疫苗接种对胚胎倍性没有不良影响。我们的发现为计划怀孕的接种女性提供了进一步的保证。需要进行未来的前瞻性队列研究,纳入更大的数据集和更长的随访时间,以确认这一结论。